



Press Release

Carl Zeiss Meditec AG and PhysiOL SA settle legal dispute

JENA, 18. August 2014

PhysiOL SA and Carl Zeiss Meditec AG have settled their legal dispute about patents and utility models for trifocal intraocular lenses (IOL) out of court. Under a Settlement agreement, the two parties have agreed to permit the unrestricted distribution of products from the FINEVISION line (PhysiOL SA) and AT LISA tri line (Carl Zeiss Meditec AG) as well as products based on this technology. Contrary to a statement made in an earlier press release by PhysiOL SA in the course of the proceedings, PhysiOL SA recognized IP rights held by Carl Zeiss Meditec AG and therefore accepted entering into an agreement with Carl Zeiss Meditec AG. Carl Zeiss Meditec AG does not make any payments to PhysiOL SA under the agreement. The information comes from both companies.

The agreement extends not only to markets protected directly by industrial property rights such as Germany, the USA and Japan, but also regions that will be covered by future rights. The agreement applies with immediate effect. Both companies have undertaken to withdraw all infringement suits, patent opposition proceedings and a cancellation request for a utility model. The specific terms of the settlement are confidential.

Intraocular lenses (IOL) are used primarily in the treatment of cataract. The development of innovative new lenses has significantly improved opportunities for treatment over the past few years. Trifocal intraocular lenses allow suitable patients good vision over all distances - in many cases, not even eyeglasses are required.

Press contact

Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG
Tel. 03641 220-331, E-Mail: press.meditec@zeiss.com

Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
Tel. 03641 220-116, E-Mail: investors.meditec@zeiss.com

www.meditec.zeiss.de/presse



Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2012/2013 (ended 30 September) the company's around 2,500 employees generated revenue of EUR 906 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65% are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress for more than 160 years and enhances the quality of life of many people around the globe. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information, please go to: www.meditec.zeiss.com